Clinical Trial Update: A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305. [Phase 3]

View source ↗

Summary

A 52-week open-label extension study following the double-blind Phase 3 efficacy and safety trial for schizophrenia (R076477-SCH-305) has been completed, sponso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED